Latest Press Releases Innate Pharma reports First Half 2024 Business Update and Financial Results September 12, 2024 Monalizumab data from NeoCOAST-2 Phase 2 study in early-stage NSCLC presented at the WCLC 2024 September 9, 2024 Innate Pharma announces conference call and webcast for first half 2024 financial results and business update September 5, 2024 Selected media ANKET: Our NK cell engager platform Thu, 06/10/2021 - 07:00 Click here to learn more about ANKETTM Read more about ANKET: Our NK cell engager platform Interview of Eric Vivier “The new generation of NK cell therapies” Fri, 02/05/2021 - 08:00 Interview Eric Vivier "The new generation of NK cell therapies" Read more about Interview of Eric Vivier “The new generation of NK cell therapies” Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity Thu, 05/30/2019 - 07:00 Read more about Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Monalizumab data from NeoCOAST-2 Phase 2 study in early-stage NSCLC presented at the WCLC 2024 September 9, 2024
Innate Pharma announces conference call and webcast for first half 2024 financial results and business update September 5, 2024
ANKET: Our NK cell engager platform Thu, 06/10/2021 - 07:00 Click here to learn more about ANKETTM Read more about ANKET: Our NK cell engager platform
Interview of Eric Vivier “The new generation of NK cell therapies” Fri, 02/05/2021 - 08:00 Interview Eric Vivier "The new generation of NK cell therapies" Read more about Interview of Eric Vivier “The new generation of NK cell therapies”
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity Thu, 05/30/2019 - 07:00 Read more about Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
